PainReform Ltd - Bagan rega PRFX

PainReform Ltd. (PRFX) has developed an advanced method for long-term postoperative pain management that minimizes the use of opioids. The high value of the PRF-110 drug is driven by its oil-based composition, which provides an effect for up to three days, ensuring stable demand from clinics. Intellectual property protection helps the brand avoid dumping and maintain profitability. The indicator is 0.75. This chart illustrates the asset's market price.

The price reflects the current market value of a single share, serving as a key criterion for compliance with US exchange listing requirements to ensure asset liquidity. Professional investors track the asset's price movements as an indicator of speculative expectations, as the absence of commercial products at PainReform Ltd. (PRFX) makes quotes dependent on test results and the rate of investment capital burn.